Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in clinical studies in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

[stock_market_widget type=”chart” symbol=”CRBP” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]